ALK and non-small cell lung carcinoma: Notably, CDA expression was higher in patient-derived resistant cells (SNU-2535, -2550, -2563) than in naïve ALK-positive NSCLC patient-derived cells (SNU-3166) at both mRNA and protein levels (Fig. 6d and Supplementary Table 8).